ArticleJournal of virology2025
Replication-driven HBV cccDNA loss in chimeric mice with humanized livers.
Article in Journal of virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Review
- Molecular insights into the mechanisms of occult hepatitis B virus infection.Archives of virology · 2026Review
- HBVZ10, an AAV8 vector-based new HBV therapy candidate for cccDNA elimination.Molecular therapy. Methods & clinical development · 2025Article
Corrections and comments
- Update of
Authors and funding
6 authors.
Funding
Abstract
Hepatitis B virus (HBV) infection depends on the establishment of covalently closed circular DNA (cccDNA) and can be either transient or persistent. Persistent infection requires a noncytopathic viral phenotype, primarily achieved by limiting replication in infected cells. This study aimed to understand how most HBV-infected cells can avoid cytopathic consequences despite robust replication. Using chimeric mice with humanized livers, we assessed HBV replication kinetics and observed a progressive accumulation of viral products from early stages up to peak infection in infected cells, but the accumulation stopped increasing upon reaching the persistence phase, possibly resulting from the inhibition of HBV replication. We then examined HBV products, including cccDNA, transcription, and viral protein levels, to identify the potential point of inhibition, finding no clear suppression of viral transcription or protein synthesis. Quantitative analysis of cccDNA levels in bulk cells, single nuclei, and individual HBsAg-positive cells revealed that cccDNA was undetectable in a portion of infected cells. Our findings raise the possibility that infected cells may spontaneously clear cccDNA. This would stop HBV replication at its root and avoid the potential cytopathic consequences in infected cells due to uncontrolled viral replication. These results suggest that efficient cccDNA elimination might be achievable without directly targeting existing cccDNA.IMPORTANCEThe primary barrier to curing chronic HBV infection is the persistence of covalently closed circular DNA (cccDNA), which is traditionally considered stable within infected cells. However, clinical observations have revealed that cccDNA can undergo frequent clearance and replacement in patients with chronic HBV infection. Building on these observations, our study demonstrated that cccDNA was undetectable in a portion of HBV-infected cells at different timepoints after peak infection in chimeric mice with humanized livers, suggesting that spontaneous cccDNA clearance may occur. These findings align with clinical data and indicate that effective cccDNA elimination may be possible without the need to target cccDNA itself directly.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.